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A combination of LC and MS was applied to an isogenic breast tumor metastasis model to iden-
tify proteins associated with a cellular phenotype. Chromatofocusing followed by nonporous-RP-
HPLC/ESI-TOF MS was applied to cell lysates of a pair of monoclonal cell lines from the human
breast carcinoma cell line MDA-MB-435 that have different metastatic phenotypes in immune-
compromised mice. This method was developed to separate proteins based on pI and hydro-
phobicity. The high resolution and mass accuracy of ESI-TOF measurements provided a good
correlation of theoretical MW and experimental Mr values of intact proteins measured in mass
maps obtained in the pH range 3.8–6.4. The isolated proteins were digested by trypsin and ana-
lyzed by MALDI-TOF MS, MALDI-QIT-TOF MS, and monolith-based HPLC/MS/MS. The
unique combination of the techniques provided valuable information including quantitation and
modification of proteins. We identified 89 selected proteins, of which 43 were confirmed as dif-
ferentially expressed. Metastasis-associated proteins included galectin-1, whereas annexin I and
annexin II were associated with the nonmetastatic phenotype. In this study, we demonstrate that
combining a variety of MS tools with a multidimensional liquid-phase separation provides the
ability to map cellular protein content, to search for modified proteins, and to correlate protein
expression with cellular phenotype.
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1 Introduction
Breast cancer is the second most common cause of cancer-
related deaths among American women, largely due to the
recurrence of disseminated disease. The ability to predict the
metastatic behavior of a patient’s tumor and to eradicate or
control recurrent disseminated malignancy remain major
clinical challenges in oncology. Unfortunately, the multistep
nature of metastasis poses difficulties in both design and
interpretation of experiments to unveil the mechanisms
causing the process. Studies on excised fixed human tissues
are complicated by the variance of genetic background be-
tween individuals and by the cellular heterogeneity of a
complex tissue mass. Thus, research into the mechanisms of
metastasis requires appropriate models which are amenable
to detailed genetic analysis. In order to facilitate the investi-
gation of this complex multistep process, we have developed
an experimental system in which the role of candidate
metastasis genes can be screened and tested [1, 2]. Mono-
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clonal cell lines M4A4 and NM2C5 are spontaneously occur-
ring sublines of the MDA-MB-435 cell breast tumor cell line
[3] which exhibit many phenotypic differences in growth,
invasion, dissemination, and spontaneous metastatic effi-
ciency from an orthotopic site. The common origin of these
cell lines enables the comparative investigation of cellular
and molecular events in the metastatic process in a stable
and isogeneic model. We have performed several studies on
these cell lines, comparing cellular and tumor morphology
[1], dissemination patterns in vivo [2], cytogenetic composi-
tion [4], and selective and global transcriptional profiles [5, 6].
However, while molecular changes during phenotypic trans-
formation clearly occur at the level of transcription, it is the
protein complement that ultimately determines the cellular
phenotype. Furthermore, changes occur not only in protein
abundance, but also involve protein structural changes such
as sequence variation or PTM. Thus, it is important to
develop rapid, accurate, and reproducible protein mapping
techniques for the study of tumor cell protein content since
many of the changes that occur in tumor cell transformation
may be manifested only in the proteome.
A 2-D liquid separation-mass mapping method has
been developed in our laboratory for the analytical profiling
of proteins in complex biological material [7–9]. The ana-
lytical approach fractionates proteins based upon pI in the
first dimension by chromatofocusing (CF), and each frac-
tion is subsequently separated based upon polarity of the
protein in the second dimension by nonporous-RP-HPLC
(NPS-RP-HPLC). The protein eluants from RP-HPLC are
directed online to ESI TOF-MS to obtain an accurate and
reproducible protein intact molecular weight. Purified pro-
teins fractionated by means of the 2-D liquid separation are
collected and stored for further analysis by peptide map-
ping using matrix-assisted laser desorption-ionization TOF
MS (MALDI-TOF MS). The combination of these methods
enables high accuracy protein profile comparisons between
biological samples. The mass mapping method also pro-
vides the ability to identify protein expression patterns that
are not based solely on abundance. The combination of
peptide mapping with the highly accurate intact protein Mr
data enables the elucidation of peptide-specific alterations.
Thus, the mass mapping technique can provide compara-
tive information on truncated or alternatively spliced pro-
tein isoforms, and on specific PTM of proteins in complex
biological samples. Furthermore, in this study we
employed monolithic capillary columns synthesized with
silica or polymer [10–12]. These columns provide a number
of distinct advantages derived from fast mass transfer
kinetics [13] due to the lack of interstitial space, and which
enable high resolution, high efficiency, and high recovery
[14] in a rapid separation time. These unique character-
istics are ideally suited for the analysis of complex pro-
teomes [7, 15, 16].
In the present study, we applied the liquid-phase 2-D
technology approach to investigate whether proteomic dif-
ferences could be found that distinguished the metastatic
M4A4 and nonmetastatic NM2C5 cell lines. Thirteen frac-
tions were collected (pH range 3.8–6.4) containing a total
of approximately 700 unique proteins from each cell line,
with molecular weights ranging from 5 to 80 kDa. Candi-
date differentially expressed proteins were subsequently
collected in the liquid phase and identified by ESI-TOF MS
and MALDI-TOF-MS mass mapping. The monolithic LC/
MS/MS proved useful in confirming protein identifications
and elucidating important PTMs. Forty-three candidate
proteins which displayed a more than two-fold difference
in expression level in metastatic cancer cells compared to
nonmetastatic cells, were identified. Twelve proteins were
up-regulated and 15 proteins were down-regulated in the
metastatic M4A4 sample. Furthermore, 16 proteins were
detected as being uniquely expressed in either cell line.
The proteomic profiling approach described here enables
the identification of phenotype-associated proteins for
subsequent functional analyses and disease biomarker
development.
2 Materials and methods
2.1 Cell lines
Human mammary tumor cell lines M4A4 and NM2C5
were derived from breast tumor cell line MDA-MB-435 as
described previously [1]. Cell lines were maintained as
subconfluent monolayer cultures in RPMI 1640 medium
(Gibco-BRL, NY) supplemented with 10% fetal calf serum
at 377C under 5% CO2/95% air. The medium was exchan-
ged every third day, and passaging was routinely per-
formed as cultures reached ,75% confluency. In order to
limit any potential biological variability when performing a
comparative profiling study of these tumor cell lines, anal-
yses were performed on cultures passaged no more than
ten times from frozen stock vials designated passage 1 at
the time of initial monoclonal expansion, and cell lines
were cultured under parallel conditions such that feeding
and passaging regime, confluency, and all serum/media
batches were exactly the same for both lines.
2.2 Sample preparation
Approximately 60–90 million cells were used for each
preparation of CF. The cell pellets were allowed to thaw at
room temperature and were quickly mixed with lysis buf-
fer. The lysis buffer was composed of 6 M urea, 2 M thio-
urea, 2% w/v n-octyl b-D-glucopyranoside (OG), 5 mM
TCEP, 1 mM PMFS (Sigma, St. Louis, MO), 10% v/v gly-
cerol, and 10 mM tris (2-carboxyethyl) phosphine. After
30 min of lysis at room temperature, the sample was
centrifuged at 35 000 rpm for 1 h at 47C. The supernatant
was recovered and total protein present was determined
using a Bradford-based assay (BioRad, Hercules, CA).
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2.3 CF
Prior to CF separation, the lysis buffer in the whole cell lysate
was replaced by a start buffer (25 mM bis-tris propane, 6 M
urea, 0.2% w/v OG, pH 6.4 6 0.1) using a PD-10 column
(Amersham Biosciences, Piscataway, NJ). The Bradford
method was performed to determine the relative protein
contents of the samples. Around 2.5 mg of buffer-exchanged
sample was loaded onto a CF column (Eprogen, Darien, IL).
The protein was eluted from the column by using a 0.2 mL/
min of an eluting buffer, which contained 8% v/v polybuffer
74 (Amersham Biosciences ), 6 M urea, 0.2% w/v OG,
pH 4.0 6 0.1. Saturated iminodiacetic acid was used to
adjust the pH of all CF buffers. Online pH measurement was
monitored by a postdetector pH flow cell (Lazer Research
Laboratories, Los Angeles, CA) and the eluent was collected
from pH 6.4 to 3.8 every 0.2 pH unit intervals. CF fractions
were stored at 2807C for further analysis.
2.4 NPS-RP-HPLC/ESI-TOF MS
The NPS-RP-HPLC experiment was performed on an
ODSIII-E (4.6 mm633 mm) column packed with 1.5 mm
C18 nonporous silica beads (Eprogen). The column was
maintained at 657C in a column heater (Timberline,
Boulder, CO) to improve the resolution and the speed of
separation. Each CF fraction was loaded for separation with
the HPLC System Gold equipped with UV detector (Beck-
man Coulter, Fullerton, CA). The solvent system, 0.1% v/v
TFA in water (solvent A) and 0.1% v/v TFA in ACN (sol-
vent B), was used to generate a gradient elution profile as
follows: 5–15% B in 1 min, 15–25% B in 2 min, 25–31% B
in 3 min, 31–41% B in 10 min, 41–47% B in 3 min, 47–
67% B in 4 min, and 67–100% B in 1 min. The flow rate
was set at 0.5 mL/min, which was split postcolumn to
produce a flow rate of 200 mL/min through a premixing
chamber and of 300 mL/min through a UV detector. A syr-
inge pump was set at 25 mL/min to deliver 10% formic
acid (Sigma) to the premixing chamber and the final flow
was delivered to the source of the ESI-TOF MS (LCT sys-
tem, Micromass, Manchester, UK) for Mr analysis of intact
proteins. The Beckman model 166 detector was set at
214 nm for detection of proteins. The proteins eluting
from the column were collected using an automated frac-
tion collector, controlled by an in-house designed DOS-
based software program. Collected fractions were subjected
to proteolytic digestion for MALDI-TOF MS analysis. For
these experiments, capillary voltage was 3250 V, desolva-
tion temperature was 3507C, source temperature was
1507C, desolvation gas flow 600 L/h, and maximum nebu-
lizer gas flow. One MS spectrum was acquired per second.
Prior to each experiment, the instrument was externally
calibrated by direct infusion of NaI-CsI solution using a
syringe pump. To assist quantitation, 1 mg of bovine insu-
lin (Sigma) was added as an internal standard to each CF
fraction prior to each run.
2.5 ESI-TOF data analysis
ESI-TOF data analysis was performed using MassLynx ver-
sion 4.0 (Waters-Micromass). The MaxEnt 1 deconvolution
algorithm was used to perform the deconvolution of the
multiple-charged-ion umbrella of the ESI-TOF MS spectrum
into a MaxEnt spectrum on a real-mass scale. The MaxEnt
peaks were converted to the intensity bars where peak height
was proportional to its peak area. For each separation,
deconvoluted molecular weights were pooled into a single
mass spectrum. They were converted to a single text file and
imported into a single mass mapping program. Multiple
separations could be combined to produce a virtual 1-D gel or
mass map, to aid in comparisons of protein levels between
different samples.
2.6 Tryptic digestion and MALDI sample preparation
The protein fractions collected from NPS-RP-HPLC were
concentrated to 20 mL using a SpeedVac concentrator (Lab-
conco, Kansas City, MO) operated at 457C. A 30 mL of 50 mM
ammonium bicarbonate (Sigma) at pH 7.8 was then added
to neutralize the remaining TFA in the samples. The sample
was vortexed and 0.5 mg of TPCK modified sequencing grade
trypsin (Promega, Madison, WI) was added for digestion.
The samples were vortexed again and incubated at 377C for
18 h. The digestion was terminated by adding 10 mL of 10%
v/v TFA to the digest. A 30 mL aliquot of tryptic digestion
mixture was dried completely and reconstituted in 5 mL of
deionized water for later monolith-based LC/MS/MS analy-
sis. The rest of the tryptic digests was desalted and con-
centrated using a 2 mm C18 ZipTip (Millipore, Bedford, MA).
The peptides were eluted in 5 mL of 60% v/v ACN with 0.5%
v/v TFA. The samples were stored for MALDI-TOF MS and
MALDI-QIT-TOF MS analysis.
2.7 MALDI-TOF MS
The matrix-standard solution was prepared by first diluting a
saturated a-CHCA (Sigma) with three parts of 1% v/v TFA
and 60% v/v ACN. Angiotensin I (1294 Da), adrenocortico-
tropic hormone (ACTH) chip 1–17 (2093 Da), and ACTH
chip 18–39 (2465 Da) were added to the diluted matrix solu-
tion to serve as internal peptide standards. The final con-
centration of each internal standard was 50 fmol in each spot
on the MALDI plate. A 1 mL aliquot of the peptide sample
was spotted on to a Micromass 96-spot plate followed by 1 mL
of matrix/internal standard solution on the top for cocrys-
tallization.
PMFs of the digest sample were generated by a TofSpec
2E (Waters-Micromass) in reflectron mode, with 20 kV total
acceleration and a pulse voltage of 2450 V at a 520 ns delayed
extracting time. The peptide masses were measured from
500 to 4000 m/z and each final spectrum was the summed
average of 80–150 spectra collected at a rate of four spectra
per second. Using the internal standard signals, the peptide
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mass spectra were internally calibrated and consistently
achieved a mass accuracy of 50 ppm or less. The Masslynx
version 4.0 (Waters-Micromass) was used to process the cali-
brated spectra and the monoisotopic experimental masses
were selected and submitted to MS-Fit (http://prospector.
ucsf.edu/ucsfhtml4.0/msfit.htm) to search the NCBI/Swiss-
Prot databases for protein identification. The search was
performed using the following parameters; (i) species: Homo
sapiens (ii) allowing one missed cleavage (iii) possible mod-
ifications: peptide N-terminal Gln to pyroGlu, oxidation of
M, protein N-terminal acetylated, and phosphorylation of S,
T, and Y (iv) MW ranged from 1000 to 100 000 and (v) pI
range of protein was 3–10. The peptide mass tolerance was
50–100 ppm.
2.8 Monolithic HPLC MS/MS
Monolithic capillary columns (200 mm id660 mm length)
were prepared by copolymerizing styrene and divinyl-
benzene according to the protocol described elsewhere [7].
The Ultra-Plus II MD Capillary Pump module (Micro-Tech
Scientific, Vista, CA) with an in-house designed column
heater was used for all chromatographic separations. The
capillary column was directly mounted on a microinjector
(model C4-1004-.5, Valco Instruments, Houston, TX) with a
500 nL internal sample loop and a microtight union with
5 nL swept volume (Upchurch Scientific, Oak Harbor, WA).
The flow rate of the solvent delivery pump was set at 0.5 mL/
min, which was split precolumn to produce a flow rate of
2.5 mL/min at 607C through the monolithic capillary column.
A mobile phase system of two solvents was used, where sol-
vents A and B were composed of 0.05% formic acid (Sigma)
in HPLC grade water (Fisher Scientific, Hanover Park, IL)
and ACN, respectively. A linear gradient of 0–100% B in
18 min was applied. In order to sequence the tryptic peptides
of interest, tandem MS experiments were performed using
linear IT MS (LTQ, Thermo Finnigan, San Jose, CA), where
the monolithic HPLC configuration described above was di-
rectly interfaced. The capillary transfer tube was set at 2007C
and ESI voltage at 4.0 kV. A sheath gas flow of 12 arbitrary
units was used. The ion activation was achieved by utilizing
helium at a normalized collision energy of 35%. All MS/MS
data obtained were analyzed using the TurboSequest feature
of Bioworks 3.1 SR1 (Thermo Finnigan). By allowing up to
two missed cleavages, peptide ions were automatically
assigned with the Xcorr values to consider .3.5 for 13 ions,
.2.5 for 12 ions, and .1.5 for 11 ions and the DCn of 0.1 or
higher [17]. The search parameters were as follows:
(i) species Homo sapiens, (ii) allowing two missed cleavage,
(iii) possible modifications were peptide N-terminal Gln to
pyroGlu, oxidation of M, protein N-terminal acetylated, and
phosphorylation of S, T, and Y, (iv) peptide toler-
ance 6 1.5 Da, (v) MS/MS tolerance 6 1.5 Da, and (vi) pep-
tide charge 11, 12, 13. Swiss-Prot database was used for
MS/MS analysis.
2.9 MALDI-QIT-TOF MS
A Shimadzu-Biotech AXIMA-QIT MALDI quadrupole IT-
TOF instrument (Shimadzu-Biotech, Manchester, UK) was
used to perform MS/MS of selected peptides. Samples were
prepared in an identical fashion to those for peptide finger-
printing. 2,5-dihydroxybenzoic acid (Sigma) was used as the
matrix at a concentration of 20 mg/mL in 1% v/v TFA, 60%
v/v ACN. The purified peptide sample (0.5 mL) was deposited
on a MALDI target plate along with 0.5 mL of the matrix so-
lution. The TOF instrument was externally calibrated using a
mixture of Bradykinin fragment 1–7, Angiotensin II, P14R,
ACTH fragment 18–39, and Insulin chain B (Sigma), typi-
cally yielding the mass tolerance of 30 ppm. The standard
instrument settings for optimum transmission at medium
mass were used to record all mass spectra in this work. Data
acquisition and processing was performed using Kompact
LAUNCHPAD™ software and the ion masses input was sub-
mitted to the Swiss-Prot database using MASCOT MS/MS
ions search (http://www.matrixscience.com). The MASCOT
search parameters were as follows: (i) species Homo sapiens,
(ii) allowing one missed cleavage, (iii) possible modifica-
tions: peptide N-terminal Gln to pyroGlu, oxidation of M,
protein N-terminal acetylated, and phosphorylation of S, T,
and Y, (iv) peptide tolerance 6 1 Da, (v) MS/MS toler-
ance 6 0.9 Da, and (vi) peptide charge 11.
2.10 Western blotting
Cell pellets were lysed on ice for 15 min with lysis/extraction
reagent (Sigma) supplemented with protease inhibitor cock-
tail (Roche Diagnostics, Indianapolis, IN). Protein con-
centration was determined using the BCA Protein Assay
(Pierce Chemical, Rockford, IL). Ten micrograms of total cell
protein extracts from each cell line, in duplicate, and Mark 12
MW standards (Invitrogen, Carlsbad, CA) were resolved by
SDS-PAGE (4–12% Bis-Tris gel, Novex, Invitrogen) under
reducing conditions and electroblotted onto a PVDF mem-
brane (Immobilon-PSQ; Millipore). One set of the immobi-
lized proteins was probed with 1 mg/mL of anti-annexin I
antibody (BD Transduction Laboratories, San Jose, CA) and
the duplicate set with a 1:5000 dilution of anti-b-actin poly-
clonal antibodies (Sigma). The binding of HRP-conjugated
secondary antibodies was detected by ECL (Amersham Bio-
sciences).
3 Results and discussion
The identification of differentially expressed proteins in cell
extracts requires a highly reproducible fractionation and
detection system. To meet these criteria, we combined a
highly reproducible 2-D liquid-phase separation by CF and
NPS-RP-HPLC approach [8, 9, 18] with the high mass accu-
racy of detection by MS or MS/MS. The flowchart in Fig. 1
shows the experimental overview from cell lyses through the
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Figure 1. Experimental overview of
the liquid-phase 2-D protein separa-
tion approach and mass spectro-
metric techniques in peptide finger-
printing and sequencing analysis for
MDA-MB-435 metastatic cell lines.
protein identification. Briefly, soluble proteins from lysed
cells are separated by their pI in the first dimension using CF.
The second dimension employs an NPS-RP-HPLC where the
proteins are separated according to their hydrophobicity. Elu-
ent from the NPS-RP-HPLC step is split postcolumn for
direct introduction to ESI-TOF MS and to a UV detector for
fraction collection for offline analysis by PMF or MS/MS. The
deconvolution of ESI-TOF MS data provides the intact mas-
ses and the relative quantitation of the proteins in the cells of
interest. The protein fractions collected from NPS-RP-HPLC
are enzymatically digested and analyzed by MALDI-TOF MS
for protein identification by PMF. In cases of ambiguity of
protein identifications by PMF, we performed MS/MS analy-
sis using capillary monolith LC separation of tryptic digests of
proteins isolated from the liquid separations, with online
detection by linear IT MS. Occasionally, the tryptic peptide
sequences that were not detected/or performed by the
monolith-based LC/MS/MS methods were successfully
sequenced by MALDI-QIT-TOF MS. Comparison of the
experimental Mr value of intact protein with database infor-
mation provides highly reliable protein identification and the
presence of possible modifications.
3.1 Protein separation and quantitation by ESI-TOF MS
Figure 2a shows an example of a CF chromatogram obtained
from a metastatic M4A4 cell lysate. The online monitored
linear gradient was superimposed on the image and 13 frac-
tions were collected in the pH range 6.4–3.8. The most acidic
and basic fractions were not mapped since there were only a
limited number of proteins detected. The second dimension
of NPS-RP-HPLC produces a 2-D UV map, as shown in
Fig. 2b. The horizontal axis is the fraction pH and the vertical
axis is the relative % hydrophobicity. Each band represents a
protein peak eluted from the RP-HPLC separation with
grayscale intensity representing the relative intensity of each
protein peak. The image offers the same advantages of dif-
ferential expression profiling provided by a 2-D gel analysis
but is obtained in digitized form. The 2-D UV maps from the
two samples are readily viewed by in-house software for
comparison, including differentially expressed and com-
mon proteins. Based on the image bands, approximately
700 proteins were collected for each cell line. An important
aspect of 2-D liquid separation is the reproducibility
achieved in the pH dimension by CF. In order to maintain
accuracy, we routinely perform duplicate evaluations of
protein content overview maps. Furthermore, three repli-
cates of CF runs pH 6.5–4.0 were performed on the M4A4
samples to monitor reproducibility. Three samples contain-
ing 2.4, 2.4, and 2.3 mg, respectively, of M4A4 protein were
loaded on to a CF column, and one pH fraction from each
CF run was separated by RP-HPLC. Figure 3A shows that
the RP-HPLC separation profiles were very similar,
confirming a high level of reproducibility of 2-D liquid
separation for intersystem comparisons via differential
mapping. In addition, a quantitative analysis of the protein
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Figure 2. (a) A CF chromatogram of the metastatic M4A4 cell
line. The UV detector was set at 280 nm and the gradient was
originated from pH 6.4 to 3.8 for 75 min. The fractions were col-
lected at every pH 0.2 unit interval. (b) A 2-D UV map of M4A4
sample. Each grayscale band represents the relative intensity of
each protein, from gray (lowest intensity) to white (highest
intensity).
bands in Fig. 3A and the other pH fractions examined (data
not shown) indicated that the error rate was less than 10% in
these experiments.
Another important feature of the use of liquid methods
for separation of proteins is the capability to directly interface
with MS. In this study, protein Mr was detected by online
analysis using the LC/ESI-TOF-MS system. In the resulting
data, the experimental Mr of the proteins closely matched the
database MW of the corresponding proteins, as shown in
Fig. 4. The intact proteins of galectin-1 and 60S ribosomal
protein L27 of the M4A4 sample were detected with a high
mass accuracy of 70 ppm. Although the mass accuracy is
dependent on the protein umbrella spectra, this method
provides much improved attainable mass accuracy (,0.1%
or 1000 ppm) compared to the 5–10% typically achieved by
2-DE [19]. Additionally, the deconvoluted spectra of intact
proteins occasionally provide additional information on the
structure of specific proteins. For example, the deconvoluted
spectrum of galectin-1 (Fig. 4A) suggested different isoforms
with possible acetylations. The different isoforms have close
pI and MW values as calculated from their protein sequences
using Compute pI/MW tool (http://ca.expasy.org/tools/
pi_tool.html). Our analysis showed that these isoforms of
Figure 3. (A) Reproducibility study of 2-D liquid separation. Three
batches of samples from the metastatic cell line M4A4 were
separated by CF. Spectra depict a single pH fraction from each
run selected for RP-HPLC analysis. (B) Representative differential
map (center) for comparison of protein expression in metastatic
cells (left) and nonmetastatic cells (right).
galectin-1 have close retention times and, hence, similar
hydrophobicities. Acetylation at the N-terminus of the first
amino acid in the galectin-1 sequence has been reported
previously [20]. Further work on the identification of addi-
tional potential modifications of galectin-1 is in progress.
The ability to obtain highly accurate Mr values revealed
acetylated isoforms of a number of other proteins present in
both cell lines (data not shown). In addition to providing
accurate Mr and structural information, ESI-TOF MS also
plays a role in accurate quantitation [21]. The resulting pro-
tein umbrella from the TOF signature is processed by Max-
Ent software to create a selected ion chromatogram (SIC) for
each detected protein [19]. The deconvoluted molecular
spectrum peak area is representative of the accurate meas-
urement of the entire amount of the protein present in the
sample. To aid in quantitative sample comparisons, 1 mg of
bovine insulin internal standard is added to the CF fraction
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Figure 4. Deconvoluted spectra
show (a) Mr of galectin-1. (b) Mr of
60S ribosomal protein L27. The
database molecular weights of
galectin-1 and 60S ribosomal pro-
tein are 14 716 and 15 667 Da,
respectively. The deconvoluted
spectra show good correlation of
experimental molecular masses and
database masses of corresponding
proteins. The mass accuracy is bet-
ter than 70 ppm.
prior to loading onto NPS-RP column. In this study, we
examined the proteins in the cell lysates from MDA-MB-435
sublines with molecular weights ranging from 5 to 80 kDa,
based on ESI-TOF measurements. Figure 5 shows repre-
sentative 2-D mass maps obtained from the online LC/MS of
CF fractions from cell lines M4A4 (metastatic) and NM2C5
(nonmetastatic). Approximately 70–80 unique proteins Mr
were detected for each CF fraction. The image is similar to
that of a 2-D gel where the vertical axis is Mr and the hori-
zontal axis is pH. The intensities of protein bands correlate
to the relative protein expression levels detected.
3.2 Identification of separated proteins by
MALDI-TOF MS
To study and identify proteins collected by RP-HPLC, a
MALDI-TOF-MS technique was employed. The isolated pro-
tein fractions underwent tryptic digestion and SPE prior to
MALDI analysis. The profiles of tryptic peptides present in
the fraction were measured using MALDI-TOF MS, in a
process referred to as PMF. The monoisotopic peaks were
selected and submitted to the NCBI/Swiss-Prot database in
MS-Fit. Certain established criteria were required for
enhancing confidence and accuracy in the search results of
which a MOWSE score of at least 1000, percent coverage of at
least 20% and proteins ranged in the top four and five mini-
mum peptide matches were accepted for protein identifica-
tions (IDs). In addition, the molecular weight of the assigned
protein must fall within 6 250 Da of the experimental Mr for
database identification. After 2-D separation, we compared
the UV maps of M4A4 and NM2C5 cell lines to view relative
differences in protein band intensities. This provides an
initial comparison of protein expression. Of the approxi-
mately 700 protein bands visualized on each UV map, 250
protein bands were selected for further analysis on the basis
of two criteria: (i) proteins revealed to be differentially
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Figure 5. Combined 2-D mass
maps for CF fractions covering
the pH range 5.4–6.2 of M4A4
(right) and NM2C5 (left) cells.
The pH of each fraction is plot-
ted vs. the Mr of the proteins
detected in that fraction. The
arrows indicate examples of dif-
ferentially expressed proteins
subsequently identified by
MALDI-TOF MS and online
monolith-LC/MS/MS. The mass
maps are shown in relative
value. The original data can be
recovered to give a detailed
view using ProteoVue software.
expressed by mass mapping and (ii) abundant proteins
present equally in both cell lines. Of the 250 proteins selected
for identification, 65 (26%) proteins were positively identi-
fied solely by the MALDI fingerprinting-mass mapping
method. The MALDI percent coverage of identified proteins
ranged between 13 and 81%.
3.3 Monolith-based HPLC/MS/MS
Obtaining high protein sequence coverage is particularly
important in a bottom-up proteomics approach for confident
protein identification. As shown in Tables 1 and 2, suffi-
ciently high protein sequence coverage obtained for most of
the proteins identified by PMF analysis strongly indicates
highly confident protein identification, supported also by
closely matching intact protein MW values. However, several
proteins were identified with a relatively low sequence cov-
erage that can lead to ambiguous identifications. This may be
due to several factors associated with the MALDI-MS experi-
ment, including peptide losses during sample clean-up pro-
cedures, varying ionization efficiencies of peptides, and de-
pendence on the choice of matrices [22]. Sequencing analysis
can provide unambiguous information on individual peptide
sequences to confirm their presence in proteins. It can also
become an additional means to further confirm the protein
identifications already obtained through PMF analysis. In
this experiment, a monolithic capillary HPLC was chosen for
online interface with a linear IT MS for sequencing analysis.
The use of monolithic capillary columns synthesized with
silica or polymer [10–12] has gained popularity as success-
fully demonstrated in the analysis of various biological
molecules [7, 15, 16]. Compared to C18 silica packed col-
umns, a monolithic column provides a number of distinct
advantages derived from fast mass transfer kinetics [13] due
to the lack of interstitial space to result in high resolution,
high efficiency, and high recovery [14] in a rapid separation
time. The fast separation speed, among many other advan-
tages over packed columns, is particularly well suited for the
rapid analysis of large numbers of proteins required in the
current study. Furthermore, its high recovery is another ad-
vantage that helps to detect peptides of low abundance or low
ionization efficiency. This leads to the analysis of the proteins
of low abundance that are known to play important roles in
proteomes where a large dynamic range presents a great
challenge. All the proteins shown in Table 3 were success-
fully analyzed by monolithic LC/MS/MS for tryptic digests by
applying data filtering criteria of high stringency. It is inter-
esting to note that the sequencing analysis based on mono-
lithic LC/MS/MS successfully identified the proteins that
went undetected by MALDI-based PMF analysis. For exam-
ple, ESI-TOF MS indicated the presence of the protein that
matched the size of ca. 50 kDa protein, which was, however,
not identified by MALDI-TOF MS. This protein was later
identified as septin-7 (Table 3) by the monolithic LC/MS/MS
through successful sequencing of five fully tryptic peptides.
The accumulating evidence suggests the involvement of
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septins in human neoplasia [23]. Although this only repre-
sents 12% of this protein sequence, it is still considered reli-
able, as two or more fully or partially sequenced peptides are
generally considered to be sufficient for confident identifica-
tion [24]. A sequencing analysis is also useful for detailed
characterization of modifications or variations of proteins to
study their significance in progression of various diseases. In
this experiment, monolithic LC/MS/MS successfully
sequenced peptides containing PTMs in several proteins.
Annexin I (annexin A1), previously identified with 39% of
sequence coverage through PMF analysis, was successfully
sequenced to result in 12 peptides, corresponding to 41% of
sequence coverage to further confirm that it was correctly
identified. Annexin I is a calcium/phospholipid-binding
protein involved in exocytosis and regulates phospholipase
A2 activity [25]. Interestingly, the monolithic HPLC/MS/MS
also characterized one of its PTMs, N-terminal acetylation
that has been reported in previous studies [26]. Figure 6
shows an annotated MS/MS spectrum obtained for one of
the tryptic peptides from annexin I, AMVSEFLK (amino acid
no. 1–8), where 42 Da mass shift, a signature of acetylation,
was clearly observed from each of the fragment type b ions
compared to the predicted fragmentation of unmodified
sequence, but not from y ions, suggesting that the modifica-
tion is present at its N-terminal end. The N-terminal acet-
ylation of annexin I was observed in both cell lines. Another
protein, histone H1.2, was also found to be acetylated at the
N-terminus through sequencing analysis. The acetylation of
SETAPAAPAAAPPAEK in mature forms of histone H1.2
has been reported [27]. The monolithic LC/MS/MS proved
very useful in elucidating and confirming protein identifica-
tions, and identifying important PTMs. In all, 65 proteins
were successfully identified solely by MALDI-TOF MS, when
the search results of the spectra met the criteria discussed in
the experimental Section 2.7. The Swiss-Prot database was
primarily considered for database searching. Accession
numbers and protein identities in Tables 1–3 were labeled as
annotated in the Swiss-Prot database unless noted otherwise.
These proteins were identified with high sequence coverage
and high MOWSE scores, which resulted in high confidence
identifications. The remaining spectra without positive
identification by PMF were selected for analysis by LC/MS/
MS or MALDI-QIT-TOF MS. Thirty proteins were positively
identified by LC/MS/MS and 12 proteins were positively
identified by MALDI-QIT-TOF MS. The selection of proteins
for LC/MS/MS and/or MALDI-QIT-TOF MS was to confirm
a number of differentially expressed proteins and to investi-
gate potential PTMs. More than 180 peptides were
sequenced in this work, of which 120 peptides were matched
to 32 unique proteins. For MS/MS analysis, the Swiss-Prot
database was used for searching protein IDs, and peptide N-
terminal Gln to pyroGlu, oxidation of M, protein N-terminal
acetylated, and phosphorylation of S, T, and Y were con-
sidered for PTM searching. Of the approximately 250 protein
bands revealed over the limited pH range, 89 (36%) proteins
were positively identified by MS or MS/MS.
3.4 Differentially expressed proteins
In the initial analysis, the 2-D UV maps provide an image
of the proteins expressed in the cell line samples. The 2-D
liquid map shown in Fig. 2B is based upon hydrophobicity.
Two maps (identical pH lanes) can be directly compared
using DeltaVue software, where the center lane displays
the difference of protein expression between the same pH
fractions for the respective samples. Figure 3B depicts the
differential maps produced using DeltaVue for two specific
pH fractions comparing M4A4 and NM2C5 cell samples.
A protein with an increased level of expression in the
metastatic sample, relative to the nonmetastatic sample,
will show up in shades of grayscale in the differential
map. When there are no changes in expression level be-
tween the two samples, the differential map will display
Figure 6. Acetylation of annexin I as
detected by online monolithic LC/MS/MS.
Comparison of predicted (unmodified) vs.
observed fragment ions for a tryptic peptide
sequence, AMVSEFLK, derived from
annexin I.
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Table 1. Proteins identified as differentially expressed (.2-fold change) in metastatic M4A4 and nonmetastatic NM2C5 cell lines using a














Up-regulated in M4A4 cells
Pyruvate kinase, isozymes M1/M2 P14618 57937/8.0 57939 57925 26 34.6
60S Ribosomal protein L24 (ribosomal protein L30) P83731 17779/11.3 17783 17781 33 4.9
40S Ribosomal protein S16 P62249 M 16445/10.2 16315 16316 47 4.2
28 kDa Heat- and acid-stable phosphoprotein Q13442 20630/8.8 20660 20664 35 4.0
Hematological and neurological expressed gene 1-like
protein variant a; ST1a
19070523 Ma) 16015/5.5 16007 16005 37 3.7
Elongation factor Tu, truncated P49411 49542/7.3 45095 45085 33 2.8
NADH-ubiquinone oxidoreductase 13 kDa-B subunit Q16718 13459/5.8 13372 13371 40 2.8
T-complex protein 1, eta subunit Q99832 59367/7.6 59436 59468 20 2.5
Nuclease sensitive element-binding protein 1 P67809 M 35924/9.9 35839 35838 55 2.3
Superoxide dismutase [Cu-Zn] P00441 15936/5.7 15891 15894 61 2.1
60S Ribosomal protein L4 P36578 47698/11.1 47658 47655 13 2.1
40S Ribosomal protein S9 P46781 22592/10.7 22463 22461 21 2.1
Up-regulated in NM2C5 cells
Annexin A2 P07355 38604/7.6 38517 38519 37 14.6
Annexin A1 P04083 38715/6.6 38673 38686 39 14.5
60 kDa Heat-shock protein, truncated P10809 61055/5.7 57966 57967 47 11.1
Heat-shock cognate 71-kDa protein (HSC70/HSP73) P11142 70899/5.4 70960 70964 35 4.8
T-Complex protein 1, b subunit P78371 57489/6.0 57486 57493 43 4.3
Heat-shock 70 kDa protein 1 (HSP70-1) P08107 70053/5.5 70068 70069 38 4.1
ATP synthase alpha chain, truncated P25705 59751/9.2 55196 55210 20 4.0
Alpha-endosulfine O43768 13389/6.6 13299 13300 52 3.8
Tumor protein D54 (hD54) (D52-like 2) O43399 22238/5.3 22360 22278 58 3.5
ATP synthase b chain, truncated P06576 56560/5.3 51827 51844 36 3.3
Platelet-activating factor acetylhydrolase IB b subunit P68402 M 25569/5.6 25527 25524 31 2.8
Myosin light polypeptide 6 P60660 16930/4.6 16875 16874 51 2.7
Ubiquitin-conjugating enzyme E2 variant 2 Q15819 16363/7.8 16275 16276 45 2.7
Putative RNA-binding protein 3 P98179 17171/8.9 17213 17217 45 2.6
Calcyclin-binding protein Q9HB71 26210/8.3 26123 26126 29 2.4
a) Accession number in NCBI database.
these bands in white. The UV intensity gives an initial esti-
mate on the expression level of each protein. However, there
is often more than one protein in a peak, and then the UV
intensity of that peak is not truly quantitative. In this case,
further fractionation is needed. To solve this problem, ESI-
TOF MS was used to separate selected proteins and quanti-
tation was achieved using an internal standard. The combi-
nation of UV maps and mass maps provides reproducible
results for quantitative study. Forty-three candidate proteins
were confirmed to be differentially expressed more than two-
fold in either direction in metastatic tumor cells compared to
isogenic, nonmetastatic tumor cells. Tables 1 and 2 summa-
rize the comparison of experimental masses and the theo-
retical intact Mr, the relative abundance and the percent
sequence coverage of the identified differentially expressed
proteins. As shown in Table 1, 12 proteins were up-regulated
and 15 proteins were down-regulated in the metastatic M4A4
sample. The observed fold changes fell between 2.1- and 4.9-
fold for most of the identified candidates, however, a few
identified proteins were found to show a .10-fold difference
in expression level. A total of approximately 700 unique pro-
teins were isolated within this study, and of those, 43 pro-
teins were ultimately identified and deemed to be .2-fold
differentially expressed between M4A4 and NM2C5. In our
previous RNA-based microarray analyses of these paired,
isogenic cell lines we found that 3 to 7% of the detected genes
were designated as differentially expressed (.2-fold change).
In line with this, the proteomic profiling revealed that ,6%
of the total proteins identified in this study were differen-
tially expressed.
A number of proteins increased in the M4A4 cells are
indicative of high metabolic activity, including pyruvate
kinase, and triose isomerase. High levels of four ribosomal
proteins also indicate a higher synthetic rate in M4A4 that
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Detected only in M4A4 cells
Galectin-1 P09382 14716/5.3 14715 nd 58 29.1
Triosephosphate isomerase P60174 26670/6.4 26541 nd 56 29.1
Nucleoside diphosphate kinase B P22392 17298/8.5 17213 nd 48 24.0
54 kDa Nuclear RNA- and DNA-binding protein Q15233 54101/9.0 54277 nd 38 12.9
Phosphoglycerate mutase 1 P18669 28804/6.7 28718 nd 38 10.7
Phosphoglycerate kinase 1 P00558 44615/8.3 44591 nd 36 8.0
Peroxiredoxin 2 P32119 21892/5.7 21811 nd 39 7.2
39S Ribosomal protein L13, mitochondrial (L13mt) Q9BYD1 20692/9.2 20604 nd 81 5.3
GST P P09211 23356/5.4 23269 nd 34 2.4
My016 protein Q9H3K6 10117/6.1 10162 nd 61 1.8
Tubulin b-5 chain (tubulin 5 b) P04350 49631/4.8 49409 nd 21 0.9
Dihydropteridine reductase P09417 25804/6.9 25743 nd 22 0.2
Detected only in NM2C5 cells
Stress-induced-phosphoprotein 1 (STI1) P31948 62640/6.4 nd 62866 15 3.6
Heat-shock 27 kDa protein P04792 22783/6.0 nd 22864 63 2.6
Mannose-6-phosphate receptor-binding protein 1 O60664 47033/5.3 nd 46954 49 2.4
Eukaryotic translation initiation factor 4H Q15056 27254/6.9 nd 27336 n/a 0.5
a) IN, normalized intensity. For quantitation of each protein, the peak area of proteins were normalized against the peak area of bovine
insulin internal standard
nd = not detected
n/a = not applicable












Histone H1.2 P16403 21221 21309 21310 3
Histone H2A type 1 P28001 14004 14004 14004 3
Histone H3.1 P68431 15273 15314 15313 2
Septin-7 Q16181 50649 50682 50681 5
Eukaryotic translation initiation factor 4H Q15056 27254 nd 27336 3
nd = not detected
may drive or facilitate cell proliferation. These findings are in
line with the fact that M4A4 cells grow more quickly than
NM2C5 in vitro and in vivo, and may confer an advantage to
M4A4 in establishing secondary tumor deposits. The annex-
ins (ANXA1 and ANXA2) were found to be very highly
expressed in the nonmetastatic NM2C5 cell line (,14-fold
relative to M4A4). These proteins belong to a family of Ca21-
dependent phospholipid-binding protein implicated in the
regulation of phagocytosis, cell signaling, and proliferation
[28]. Relatively, little is known about annexin I (lipocortin I)
expression in human cancer, but a previous study reported
that annexin I was up-regulated in a highly metastatic lung
carcinoma cell line compared to its expression in a less
metastatic counterpart [29]. Studies have reported reduced
ANXA1 expression in advanced head and neck cancers, par-
ticularly in tumors with nodal metastases [30]. A proteomic
analysis of the tumor tissue–blood interface identified
annexin I as a selective, tumor-associated endothelial cell
target in solid tumors. Subsequent radio-immunotherapy
targeted to annexin I was shown to destroy tumors and
increase animal survival [31]. In addition, annexin II expres-
sion is observed to be down-regulated in prostate cancer and
in human osteosarcoma metastases [32, 33]. The results
from these studies support the association of increased
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annexin I and annexin II expression with a less aggressive
nonmetastatic phenotype. Annexin I is also an endogenous
anti-inflammatory mediator that operates to counteract the
process of leukocyte extravasation [34]. As annexin I was
more highly expressed in nonmetastatic NM2C5 cells (Fig. 7),
it is feasible that it affects the ability of these cells to extra-
vasate at distal sites, a process thought to be essential in
metastatic sufficiency. This potential role for annexin I fits
with our previous work regarding the clinical relevance of
our metastasis model. Through green fluorescent protein
labeling of the cell lines [2], we have demonstrated the ability
of disseminated, nonmetastatic NM2C5 cells to survive and
remain dormant in the tissues of a murine host for extended
periods of time. Their failure to form metastases was not
attributable to any intrinsic loss of proliferative capacity, as
demonstrated by the ability of the cells to grow exponentially
and indefinitely when retrieved from the lung tissue and
recultured in vitro or reinoculated into the mammary gland.
Therefore, NM2C5 cells remain immortal but are unable to
complete an essential step in the metastatic cascade. This
dormancy phenomenon is observed in human patients with
breast cancer, whereby cells disseminated prior to removal of
the primary tumor can be “reactivated” and form metastases
several years later, and this is the major reason for the use of
postsurgical, adjuvant treatment. This study has encouraged
us to pursue a possible role for annexin I with respect to
tumor cell dormancy and the metastatic efficiency of NM2C5
cells.
Our proteomic analysis also revealed that 16 proteins
were uniquely expressed in either cell line (Table 2). While
trace amounts of the protein may be undetected in a given
sample, by using this method we can detect as little as 50 pg
(,100 fmol) of a 40 kDa protein [21] which is comparable to
silver staining methods. The majority of these factors were
observed to be uniquely expressed at very high levels in the
metastatic M4A4 cells. Galectin-1 and nucleoside diphos-
phate kinase B (NM23?H2) were highly expressed in the
M4A4 sample. The role of galectin-1 in cancer progress has
been widely investigated and proposed as a potential bio-
marker of metastatic tumors [35, 36], as well as a target for
anticancer drugs [37]. This protein is a member of the
b-galactoside-binding proteins, reported to act as an auto-
crine negative growth factor that regulates cell proliferation
[38] and is implicated in modulating cell–cell and cell–matrix
interactions [39]. Gal-1 is expressed in many malignant and
normal tissues, but a correlation of increased Gal-1 has been
in breast carcinomas with metastatic propensity [40]. Fur-
thermore, Gal-1 has recently been shown to be regulated
coordinately with ERBB2, a protein overexpressed owing to
gene amplification in 25–30% of breast carcinomas with a
poor clinical prognosis [41]. NM23?H2 is a multifunctional
enzyme which can cleave DNA and regulate transcription of
specific genes through multiple mechanisms, and thus can
have profound effects on the cellular phenotype dependant
on context [42]. While reduced expression of NM23.H1 has
been reported to be concordant with the presence of lymph
Figure 7. Western blot of
annexin I expression in the
metastatic M4A4 cell line,
and the isogenic, nonmeta-
static NM2C5 cell line. Esti-
mation of equal lane load-
ing was achieved using an
anti-b-actin antibody.
node metastasis or local invasiveness of the primary tumor,
this is not so for NM23.H2 [43, 44]. The expression of certain
groups of heat-shock proteins has been described in the lit-
erature as a prognostic factor in many tumors. As molecular
chaperones, these proteins play an important role in multi-
ple cellular mechanisms. Here we identified several heat-
shock proteins as being differentially expressed, notably
HSP70. The heat-shock cognate 71-kDa protein (HSC70/
HSP73) was found to be elevated five-fold in NM2C5 cells.
This protein has been reported to have an important role in
HCV-related hepatocellular carcinoma [45] and in the context
of metastasis, a recent report has shown that HSP73 binds
the chemokine receptor CXCR4 [46], a surface molecule with
a well-documented role in metastatic sufficiency in a number
of cancers [47], including breast [48, 49]. Although CXCR4
itself is not differentially expressed in our model [6], HSP73
may act downstream to differentially regulate the CXCR4
signaling pathway. Recent, large-scale microarray analyses of
human tissue specimens are building consensus genetic
profiles of breast tumors and have begun to define expres-
sion profiles which purport to predict the likelihood of breast
cancer metastases and clinical outcome [50]. It is interesting
that some of the proteins identified as being associated with
metastatic sufficiency in this study are present in a proposed
70-gene breast prognosis signature. Members of the GST
family, highly expressed in M4A4, and the ubiquitination
pathway, down-regulated in M4A4 are regulated in the same
direction in the proposed prognosis signature.
We have previously subjected the breast metastasis
model to genomic profiling approaches. Both PCR-based [5]
and oligonucleotide microarray-based global expression [6]
analyses identified a number of genes as being differentially
expressed in the NM2C5 and M4A4 cell lines, relative to one
another. Both annexins I and II expression was identified at
the transcriptional level to be 3- to 5-fold increased in NM2C5
cells. Our proteomic analysis confirmed the differential
expression of these proteins, and in this case, at higher levels
than genomic analyses suggested. Conversely, the marked
differential expression of the heat-shock protein family was
missed using genomic analyses alone, suggesting that the
expression of these proteins is primarily regulated at the
translational level. Proteomic and genomic analyses have
different advantages and the combination of both disciplines
is likely the most fruitful approach. Genomic profiling cer-
tainly has the ability to query many more targets in a single
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experiment, and supposed whole-genome coverage is fea-
sible with this platform. However, it is clear that the func-
tional endpoint of the genetic blueprint lies at the protein
level, and that the levels of messenger RNA and protein do
not always correlate well. This latter fact means that global
transcriptional approaches require considerable validation at
protein levels. Most importantly, the pivotal regulatory points
of translation and PTM of proteins such as proteolytic pro-
cessing, phosphorylation, or glycosylation can only be found
using a multidimensional proteomics approach such as that
employed in this study. These PTMs can influence the
stability, activity, localization, and structural conformation of
the protein. Thus, while genomic approaches can rapidly
create gene lists for subsequent analysis, it is important to
identify global changes in protein expression in disease
states, including metastasis. Continued improvements in
MS techniques should only accelerate the pace of discovery
in this field.
4 Concluding remarks
Breast cancer has a great propensity to develop distant
metastasis, and micrometastases may already be present at
the time of primary tumor detection. Therefore, much effort
is now being directed at finding an early marker in the pri-
mary tumor that could indicate its metastatic potential. In an
effort to establish a methodological framework for analysis of
molecules and mechanisms involved in this complex multi-
step process, we have developed a well-defined experimental
system in which the role of candidate genes can be screened
and tested. The unique advantage of the MDA-MB-435
metastasis model is the ability to profile cells of opposing
metastatic phenotype that originate from a common genetic
background. These cell lines constitute a stable and access-
ible model for the identification of genes involved in the
multistep process of breast tumor metastasis. Manipulation
of candidate genes in these cells and subsequent analysis of
upstream and downstream effects will permit evaluation of
their functional significance in the geometric progression of
breast cancer.
In this study, we have identified a number of proteins
that may participate in the processes associated with the
metastasis of breast cancer, including metabolism, cell
motility and invasion, and signal transduction. These find-
ings demonstrate that the mass mapping technique is a
powerful tool for the detection and identification of proteins
in complex biological samples and which are specifically
associated with a cellular phenotype. We have further devel-
oped multidimensional liquid-phase separation for protein
separation and show the capabilities of interfacing this tech-
nique to multiple mass spectrometric methods. CF followed
by NPS-RP-HPLC/ESI-TOF MS provides the means of accu-
rate interlysate comparison based upon the high resolution
and mass accuracy of Mr. It is important to develop rapid,
accurate, and reproducible protein mapping techniques for
the study of tumor cell protein content since many of the
changes that occur in tumor cell transformation may be
manifested only in the proteome. The sequence and struc-
ture of expressed proteins, elucidated by monolith-based
HPLC coupled with a linear IT MS, revealed that many of the
proteins in these cell lines displayed substantial PTMs and
enabled us to detect and identify several metastasis-asso-
ciated proteins that we had not found previously using
genomic screening approaches. The multidimensional pro-
teomic approach led to the identification of 24 proteins that
were overexpressed in metastatic cells relative to their iso-
genic, nonmetastatic counterparts. Although further analy-
sis will be required to fully characterize these proteins and
their role in specific cellular phenotypes, our findings
demonstrate that the combination of multidimensional
liquid-phase separation to MS or MS/MS can accurately
identify potential protein biomarkers of disease in complex
biological materials.
The liquid separation-mass mapping method provides a
means of separating and mapping hundreds of proteins
which can be displayed in a 2-D image and where each pro-
tein can be tagged according to an exact Mr, pI, and hydro-
phobicity. The ability to obtain an accurate Mr value is an
essential piece of information to confirm the identity of pro-
teins. This improved accuracy will greatly facilitate the
establishment of mass mapping databases for online query.
Through comparison of such maps we will be able to identify
subtle changes in human cell protein profiles that will, in
turn, reveal trends in protein expression changes that corre-
late with disease status. Ultimately, the ability to identify
those proteins involved in the progression of carcinoma will
most readily lead to clinically useful markers for diagnosis
and prognosis, and provide novel targets for in vivo imaging
and therapeutic targeting.
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